Skip to main content

Table 2 a) Observed group mean values (± SD) for α-synuclein at inclusion (baseline), and after one and two years, and b) predicted mean value (95 % CI) at baseline, together with estimated mean change (95 % CI) from baseline valuesa

From: Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer’s disease, mild cognitive impairment, or healthy controls: a two year follow-up study

 

α-synuclein (pg/mL)

  
 

AD-AD

MCI-AD

MCI-MCI

CTR

p-valueb

p-valuec

a)

 Baseline

494.4 ± 275.0

671.8 ± 383.1

568.6 ± 390.5

514.4 ± 263.1

0.26

 

 1 year

466.0 ± 324.8

650.9 ± 458.4

559.5 ± 339.6

na

  

 2 years

439.4 ± 285.5

587.4 ± 386.5

565.7 ± 393.3

na

  

b)

 Baseline

477.3 (333.3,621.4)

661.7 (514.3,809.0)

568.6 (415.4,721.2)

 

0.22

 

 Mean change

     

0.93

 After 1 year

−11.3 (−76.9, 54.3)

−16.7 (−85.8, 52.3)

−9.0 (−77.8, 59.7)

 

0.23

 

 After 2 years

−9.0 (−77.7, 59.7)

−42.0 (−112.2, 28.1)

0.02 (−69.9, 69.9)

 

0.33

 

 Linear trendd

−4.6 (−38.6, 29.4)

−21.0 (−55.7, 13.7)

−0.09 (−34.6, 34.5)

  

0.67

  1. Na not applicable
  2. aResults based on linear mixed model with subject as random factor (two extreme values excluded)
  3. bF-test for overall difference in mean α-synuclein levels between study groups (one-way ANOVA), or between patient groups (LMM)
  4. cF-test for heterogeneity in mean change over time in α-synuclein between patient groups (categorical and linear interaction, respectively)
  5. dMean change per year, based on model with linear time trend